Sernova, Seraxis sign definitive merger agreement
Sernova Biotherapeutics and Seraxis Holdings announced a definitive agreement to combine their technologies and businesses into BetaNova Biotherapeutics, a clinical-stage type 1 diabetes islet cell-replacement company.
Story updates
11:12:33 AM UTC
SquawkNews
Sernova and Seraxis will merge to form BetaNova Biotherapeutics, combining their cell therapy platforms to target type 1 diabetes. The deal includes $10M in financing, aims for a NASDAQ listing in Q1 2027, and expects to begin clinical trials for its lead therapy in early 2027.Original document: Se…
Sernova and Seraxis will combine to form BetaNova Biotherapeutics, bringing together their cell therapy platforms to target type 1 diabetes. The deal includes $10M in financing, with the company aiming for a NASDAQ listing in Q1 2027 and expecting to begin clinical trials for its lead therapy in early 2027.